Medicine, Infectious Diseases Division

Grants

Grants per year 1997 2014 2015 2018 2020 2027

• 1 Not started
• 149 Active
• 409 Finished

Grants per year

Search results

• Prot # BCX1812-303: A Phase 3, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Adult and Adolescent Hospitalized Subjects with Confirmed or Suspected Influenza Infection

  Ison, M. G.

  Quintiles, Inc., BioCryst Pharmaceuticals

  9/28/09 → 9/27/12

  Project: Research project

• Prot #CACZ885D2310: Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients with COVID-19-Induced Pneumonia (CAN-COVID)

  Taiwo, B. O.

  Novartis Pharmaceuticals Corporation

  4/14/20 → 10/31/21

  Project: Research project

• Prot# CI06-003: Multicenter Evaluation of The Effectiveness of Source Control With Daily Chlorhexidine Skin Preparation in Reducing Nosocomial Infections Including MRSA and VRE

  Bolon, M. K.

  Sage Products Inc.

  3/23/07 → 9/23/09

  Project: Research project

• Prot# CID 0910-Nucleosides and Inflammation, Coagulation and Endovascular Function The (NICE) Study. A Cross-Sectional Assessment of Markers Inflammation, Coagulation and Endothelial Function Among Patients Receiving Nucleoside Reverse Transcriptase Inhib

  Taiwo, B. O., Achenbach, C. J. & Palella Jr, F. J.

  University of North Carolina at Chapel Hill, GlaxoSmithKline plc

  5/25/10 → 5/25/13

  Project: Research project

• Prot# CI-PSI-RCV-04-201: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Exploring the Safety, Tolerability, & Antiviral Effect of Substituting 600mg of Racivir®(RCV) for Lamivudine(3TC) in HIV-Infected Subjects Who Have the M184V Mutati

  Palella Jr, F. J.

  Ingenix Pharmaceutical Services, Inc., Pharmasset, Inc.

  10/25/04 → 3/26/08

  Project: Research project

• Prot# CMX001-104/A03: A Multicenter, Randomized, Double-Bind, Placebo-Controlled, Multiple Dose Study of the Safety, Tolerability and Population Pharmacokinectics of CMX001 in Post-Transplant Subjects with BK Virus Viruria

  Ison, M. G.

  PPD Development, Chimerix, Inc.

  2/2/09 → 2/2/12

  Project: Research project

• Prot # CMX001-301: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic

  Ison, M. G.

  PRA Health Sciences, Chimerix, Inc.

  9/27/13 → 9/27/18

  Project: Research project

• Prot# CSP012: Evaluation of the Flu A+B Test Versus Viral Culture Using Clinical Nasal Swab Samples from Patients with Suspected Influenza Infections

  Noskin, G. A.

  Response Biomedical Corporation

  2/14/08 → 2/14/11

  Project: Research project

• Prot# CT-BI Vacc-4x 2007/1: A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART

  Taiwo, B. O.

  Constella Group, Ltd., Bionor Immuno AS

  11/14/08 → 11/13/11

  Project: Research project

• Prot# EraMune 02: Multicenter, Randomized, Non-Comparative, Controlled Study of Therapeutic Intensification plus Immunomodulation in HIV-Infected Patients with Long-Term Viral Suppression

  Murphy, R. L.

  ORVACS

  12/17/09 → 12/17/15

  Project: Research project

• Prot #GSK 201585: A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpivirine from current INI- NNRTI-, or PI

  Taiwo, B. O.

  PPD Investigator Services, LLC, GlaxoSmithKline LLC

  2/7/17 → 2/7/20

  Project: Research project

• Prot #GSK 204862: TANGO: A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority Study Evaluating the Efficacy, safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed

  Taiwo, B. O.

  PPD Investigator Services, LLC, GlaxoSmithKline LLC

  4/4/18 → 4/4/21

  Project: Research project

• Prot # GS-US-218-1227: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respiratory Syncytial Virus (RSV) Infection

  Ison, M. G.

  PPD Development, Gilead Sciences, Inc.

  11/13/14 → 11/13/17

  Project: Research project

• Prot #GS-US-218-1797: A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients with Respiratory Syncytial Virus (RSV) Infection

  Ison, M. G.

  PPD Development, Gilead Sciences, Inc.

  8/29/16 → 8/29/19

  Project: Research project

• Prot# GS-US-236-0115: A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/ Emt

  Achenbach, C. J., Palella Jr, F. J. & Taiwo, B. O.

  Gilead Sciences, Inc.

  1/16/12 → 1/16/15

  Project: Research project

• Prot#GS-US-264-0106: A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fuma

  Palella Jr, F. J.

  Gilead Sciences, Inc.

  3/15/11 → 3/15/14

  Project: Research project

• Prot #GS-US-292-0104: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positi

  Achenbach, C. J.

  PPD Development, Gilead Sciences, Inc.

  5/15/13 → 8/31/20

  Project: Research project

• Prot# INCB 08721-204: DECLARE 1 (DExelvucitabine Compared to Lamivudine in Anti-Retroviral Experienced Subjects-1)A Rndmzd, Dbl-Blnd, Phs II Study Comparing the Anti-Retroviral Safety & Efficacy of Dexelvucitabine(DFC)200mg 1x Daily to

  Sutton, S. H.

  PPD Development, Incyte Corporation

  5/18/06 → 5/1/07

  Project: Research project

• Prot# INCB 8721 RVT-203: A Placebo-Controlled, Double-Blind, Parallel Dose Group Study Exploring the Safety, Tolerability, & Virological Effect of 50, 100, & 200mg Reverset? (RVT) in HIV-Infected Antiretroviral Therapy-Experienced Subjects When Used in Co

  Murphy, R. L.

  Quintiles, Inc., Incyte Corporation

  9/8/04 → 4/13/07

  Project: Research project

• Prot# INCB 8721 RVT-901: A Long-Term Open-Label Non-Randomized Study to Evaluate the Safety of 100 and 200mg Reverset? (RVT) in HIV-Infected Antiretroviral Therapy-Experienced Subjects When Used in Combination with Other Antiretroviral Agents

  Palella Jr, F. J.

  Quintiles, Inc., Incyte Corporation

  4/7/05 → 8/6/08

  Project: Research project

• Prot#ING111762: A Phase III Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator Selected Background Regimen Over 48 Weeks in HIV-1 Infected,

  Taiwo, B. O.

  GlaxoSmithKline plc, ViiV Healthcare

  2/1/11 → 2/1/14

  Project: Research project

• Prot# MANON 02: A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Immunogenicity and the Safety of Two Schedules of an Homologous Prime-Boost with the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients

  Murphy, R. L.

  ORVACS

  11/29/04 → 12/31/07

  Project: Research project

• Prot# NV-02B-007: A Randomized, Double Blind Trial of LdT (Telbivudine) versus Lamivudine in Adults with Compensated Chronic Hepatitis B

  Palella Jr, F. J.

  Quintiles, Inc., Idenix Pharmaceuticals, Inc.

  3/24/03 → 8/8/07

  Project: Research project

• Prot# NV-02B-022: An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies

  Palella Jr, F. J.

  Quintiles, Inc., Idenix Pharmaceuticals, Inc.

  7/15/05 → 8/6/08

  Project: Research project

• Prot# NV20234: A Double-Blind, Randomized, Stratified, Multi-Center Trial Evaluating Conventional and High Dose Oseltamivir in the Treatment of Immunocompromised Patients with Influenza

  Ison, M. G.

  Quintiles, Inc., Hoffman-La Roche, Inc.

  10/25/07 → 11/30/12

  Project: Research project